Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics for recently diagnosed CD. Among the biologics, TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) are the mainstays of treatment, but newer therapies, including Takeda’s Entyvio and Janssen’s Stelara, have a growing market share.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies
United States
Real World data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants
Key Analysis provided
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.